Development PipelineTisotumab vedotin

an investigational antibody–drug conjugate directed to tissue factor

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.